Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in first quarter 2020 Flexion implementing broad cost savings initiatives; guiding to total operating expenses in the range of $167 …